Compare ImmunityBio Inc. Common Stock (IBRX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs GeneDx Holdings Corp — how do they compare? ImmunityBio Inc. Common Stock trades at $10.55 (market cap $10.51B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: ImmunityBio Inc. Common Stock is far larger — about 5.2× GeneDx Holdings Corp's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 1 Days and GeneDx Holdings Corp for 19 Days on average.
| IBRX | WGS | |
|---|---|---|
Market Cap | $10.51B | $2.02B |
Volume | 10,445,785 | 734,640 |
Sector | Health | Health |
52-Week High | $11.55 | $167.51 |
52-Week Low | $1.98 | $34.51 |
Typical Hold Time | 1 Days | 19 Days |
Enterprise Value | $10.97B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
